Article
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Aug 2011
Irvin William J, Walko Christine M, Weck Karen E, Ibrahim Joseph G, Chiu Wing K, Dees E Claire, Moore Susan G, Olajide Oludamilola A, Graham Mark L, Canale Sean T, Raab Rachel E, Corso Steven W, Peppercorn Jeffrey M, Anderson Steven M, Friedman Kenneth J, Ogburn Evan T, Desta Zeruesenay, Flockhart David A, McLeod Howard L, Evans James P, Carey Lisa A
Abstract excerpt
PURPOSE: We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism. PATIENTS AND METHODS: One hundred nineteen patients on tamoxifen 20 mg daily ≥ 4 months and not on any strong CYP2D6 inhibiting medications...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.